Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes

June 2011

Reps will be promoting Tradjenta (TRAD-gen-ta), a new gliptin for type 2 diabetes.

Tradjenta (linagliptin) is a "me too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.

Tradjenta's only real claim to fame is that it doesn't require a lower dose for patients with impaired renal function.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote